Zetagen Therapeutics secures $10m to boost cancer treatment innovations
Zetagen Therapeutics, a biopharmaceutical firm specializing in advanced treatments for metastatic cancers, has successfully secured a substantial $9.79 million in its Series B funding round. The company is renowned for its relentless pursuit of innovations targeting cancers affecting bones and soft tissue organs as well as osteologic interventions. CEO Joe C. Loy expressed his optimism, […]